Recruiting

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: Biological: bevacizumab, Biological: cetuximab, Drug: fluorouracil, Drug: irinotecan hydrochloride, Drug: leucovorin calcium, Drug: oxaliplatin
Phase: Phase III

Recruiting

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Conditions: Neoplasm Metastasis, Colorectal Cancer
Interventions: Drug: 5-FU, Drug: folinic acid, Drug: irinotecan, Drug: cetuximab, Drug: bevacizumab
Phase: Phase III

Recruiting

Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma
Conditions: Advanced Colorectal Cancer
Interventions: Drug: capecitabine + bevacizumab, Other: observation
Phase: Phase III

Recruiting

Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)
Conditions: Colorectal Neoplasms
Interventions: Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab, Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab, Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab
Phase: Phase III

Recruiting

A Study in Second Line Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: Biological: Ramucirumab, Drug: Irinotecan, Biological: Placebo, Drug: Folinic Acid, Drug: 5-Fluorouracil
Phase: Phase III

Recruiting

Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Conditions: Colorectal Cancer
Interventions: Drug: bevacizumab, erlotinib, Drug: bevacizumab, Drug: bevacizumab, Drug: low dose capecitabine
Phase: Phase III

Recruiting

Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
Conditions: Colorectal Cancer Metastatic
Interventions: Drug: Capecitabine, Drug: Bevacizumab, Drug: Capecitabine, Drug: Irinotecan, Drug: Bevacizumab
Phase: Phase III

Recruiting

Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Conditions: Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity
Interventions: Biological: bevacizumab, Drug: capecitabine, Drug: fluorouracil, Drug: leucovorin calcium, Drug: oxaliplatin
Phase: Phase III

Recruiting

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
Conditions: Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions: Drug: Pegfilgrastim, Drug: Placebo
Phase: Phase III

Recruiting

Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: Biological: bevacizumab, Drug: fluorouracil, Drug: irinotecan hydrochloride, Drug: leucovorin calcium
Phase: Phase II

Recruiting

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Conditions: Metastatic Colorectal Cancer, EGFR-Expressing Metastatic CRC
Interventions: Drug: Sorafenib (Bay 43-9006), Biological: cetuximab, Genetic: proteomic profiling, Other: immunoenzyme technique, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Other: pharmacological study, Procedure: biopsy
Phase: Phase II

Recruiting

Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth
Conditions: Colorectal Neoplasms, Liver Neoplasms
Interventions: Procedure: immediate surgery (resection of primary colorectal tumor), Drug: neo-adjuvant treatment with bevacizumab, Drug: neoadjuvant treatment with capecitabine and oxaliplatin, Drug: neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin
Phase: Phase II

Recruiting

Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
Conditions: Metastatic Colorectal Cancer
Interventions: Drug: Capecitabine, Drug: Bevacizumab, Drug: Irinotecan
Phase: Phase II

Recruiting

Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
Conditions: Colorectal Cancer
Interventions: Drug: Oxaliplatin, Drug: 5-Fluorouracil, Drug: Leucovorin, Drug: Bevacizumab, Drug: Irinotecan, Drug: Cetuximab
Phase: Phase II

Recruiting

A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
Conditions: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-FU, Drug: 5-FU, Drug: Leucovorin, Drug: 5-FU, Drug: Irinotecan
Phase: Phase II

Recruiting

Phase II Study of Neo Adjuvant Treatment With Avastin, Xeloda and/or Eloxatin in Colorectal Cancer
Conditions: Advanced Colorectal Cancer
Interventions: Drug: Oxaliplatin, Drug: Bevacizumab, Drug: Capecitabine, Radiation: radiotherapy
Phase: Phase II

Recruiting

Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer
Conditions: Colorectal Neoplasms
Interventions: Drug: Sorafenib, Drug: Placebo, Drug: Oxaliplatin or Irinotecan, Drug: Leucovorin, Drug: 5-Fluorouracil
Phase: Phase II

Recruiting

Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Conditions: Colorectal Cancer
Interventions: Drug: CS-7017, Drug: Placebo
Phase: Phase II

Recruiting

Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: Biological: bevacizumab, Drug: XELOX regimen, Drug: hydroxychloroquine
Phase: Phase II

Recruiting

A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Conditions: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: capecitabine [Xeloda], Drug: oxaliplatin
Phase: Phase II

Recruiting

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
Conditions: Colorectal Cancer
Interventions: Biological: cetuximab, Biological: ramucirumab, Drug: irinotecan hydrochloride
Phase: Phase II

Recruiting

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer
Conditions: Colon Cancer, Rectal Cancer
Interventions: Biological: IMC-1121B, Biological: IMC-18F1, Drug: mFOLFOX-6
Phase: Phase II

Recruiting

Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
Conditions: Colorectal Cancer
Interventions: Drug: AZD6244, Drug: Irinotecan
Phase: Phase II

Recruiting

Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients
Conditions: Asian Colorectal Cancer Patients
Interventions: Drug: Regorafenib
Phase: Phase II, Phase III

Recruiting

Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: Drug: chemotherapy
Phase: Phase II

Recruiting

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in K-RAS/BRAF Mutant Metastatic Colorectal Cancer
Conditions: Colorectal Cancer Metastatic
Interventions: Drug: Regorafenib (BAY 73-4506), Drug: FOLFIRI, Drug: Placebo, Drug: FOLFIRI
Phase: Phase II

Recruiting

Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: Drug: SB injection
Phase: Phase II

Recruiting

Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
Conditions: Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: Drug: oxaliplatin, Drug: leucovorin calcium, Drug: fluorouracil, Biological: bevacizumab, Procedure: therapeutic conventional surgery, Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, Other: laboratory biomarker analysis, Other: pharmacological study, Drug: irinotecan hydrochloride
Phase: Phase II

Recruiting

MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Conditions: Colorectal Neoplasms
Interventions: Drug: MK-2206, Drug: AZD6244
Phase: Phase II

Recruiting

Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: Drug: linifanib
Phase: Phase II

Recruiting

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
Conditions: Colorectal Cancer, Colorectal Adenocarcinoma
Interventions: Drug: Brivanib, Drug: Irinotecan
Phase: Phase II

Recruiting

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: Drug: bevacizumab, Drug: FOLFIRI regimen, Drug: mFOLFOX6
Phase: Phase II

Recruiting

A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: mFOLFOX6
Phase: Phase II

Recruiting

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: Drug: onartuzumab [MetMAb], Drug: Placebo, Drug: bevacizumab [Avastin], Drug: FOLFOX regimen, Drug: leucovorin, Drug: 5-FU
Phase: Phase II

Recruiting

DCE-MRI PET Bevacizumab Study in Rectal Cancer
Conditions: Rectal Cancer Patients
Interventions: Other: Bevacizumab 5 mg/kg
Phase: Phase II

Recruiting

Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy
Conditions: Rectal Cancer
Interventions: Drug: capecitabine, oxaliplatin, bevacizumab
Phase: Phase II

Recruiting

Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
Conditions: Colorectal Cancer
Interventions: Drug: Oxaliplatin, Drug: Folinic Acid, Drug: 5-fluoro-uracil, Drug: Irinotecan, Drug: Bevacizumab, Drug: Cetuximab
Phase: Phase II

Recruiting

Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
Conditions: Colorectal Cancer
Interventions: Drug: Oxaliplatin, Drug: Folinic Acid, Drug: 5-fluoro-uracil, Drug: Irinotecan, Drug: Irinotecan, Drug: Bevacizumab, Drug: Cetuximab
Phase: Phase II

Recruiting

Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Conditions: Colorectal Cancer Metastatic
Interventions: Drug: Chemotherapy
Phase: Phase II

Recruiting

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Conditions: Colorectal Cancer
Interventions: Drug: Tivozanib, Drug: Bevacizumab, Drug: mFOLFOX6
Phase: Phase II

Recruiting

Axitinib as Maintenance Treatment in Patients With Metastatic CRC
Conditions: Colorectal Carcinoma
Interventions: Drug: axitinib, Drug: placebo
Phase: Phase II

Recruiting

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
Conditions: Colorectal Cancer
Interventions: Drug: Axitinib, Drug: Bevacizumab, Drug: 5-FU, Drug: 5-FU, Drug: Leucovorin, Drug: Oxaliplatin
Phase: Phase II

Recruiting

Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: Drug: Endostatins (Endostar), Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-fluorouracil
Phase: Phase II

Recruiting

Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer
Conditions: Metastatic Colorectal Cancer
Interventions: Drug: Bevacizumab plus alternating Xelox/Xeliri
Phase: Phase II

Recruiting

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib Tablets in the Treatment of Advanced Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: Drug: Apatinib, Drug: apatinib
Phase: Phase II

Recruiting

A Trial Evaluating Raltitrexed, Oxaliplatin and Bevacizumab Combination Versus FOLFOX6 Plus Bevacizumab in 2nd-line Treatment of Metastatic Colorectal Cancer
Conditions: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab, oxaliplatin and 5FU combination, Drug: Bevacizumab, oxaliplatin and raltitrexed combination
Phase: Phase II

Not yet recruiting

IXO+A in mCRC With Liver-only Metastases
Conditions: Metastatic Colorectal Cancer
Interventions: Drug: irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab
Phase: Phase II

Not yet recruiting

Study to Evaluate Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer
Conditions: Colorectal Cancer Metastatic
Interventions: Drug: Oxaliplatin, 5FU/LV, Bevacizumab, Drug: 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
Phase: Phase II

Not yet recruiting

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
Conditions: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab, Drug: MEGF0444A, Drug: mFOLFOX6, Drug: placebo
Phase: Phase II

Not yet recruiting

First-Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Conditions: Colorectal Cancer
Interventions: Biological: bevacizumab, Drug: FOLFIRI regimen, Drug: FOLFIRI-bevacizumab regimen, Drug: FOLFOX regimen, Drug: fluorouracil, Drug: irinotecan hydrochloride, Drug: leucovorin calcium, Drug: oxaliplatin, Other: laboratory biomarker analysis, Procedure: quality-of-life assessment
Phase: Phase II

Not yet recruiting

BKM120 in Cancers With PIK3CA Activating Mutations
Conditions: Lung Cancer, Breast Cancer, Colorectal Cancer, Cholangiocarcinoma, Solid Tumors
Interventions: Drug: BKM120
Phase: Phase II

Not yet recruiting

Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer
Conditions: Metastatic Colorectal Cancer, Colorectal Cancer
Interventions: Drug: MORAb-004, Drug: Placebo
Phase: Phase II

Not yet recruiting

Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases
Conditions: Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer
Interventions: Drug: 5-FU, Folinic Acid, Oxaliplatin, Bevacizumab, Panitumumab
Phase: Phase II

Not yet recruiting

TRICC-C: BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
Conditions: Colorectal Cancer
Interventions: Drug: mFOLFOX6 + BIBF 1120, Drug: mFOLFOX6+placebo
Phase:

Not yet recruiting

TRICC-C: BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
Conditions: Colorectal Cancer
Interventions: Drug: mFOLFOX6 + BIBF 1120, Drug: mFOLFOX6+placebo
Phase: